PGR and breast cancer: We initially sought to determine whether exposure to medroxyprogesterone acetate (MPA), a synthetic progestin widely used in the United States and other countries, affected the transcriptional expression of primiR-190 and primiR-199 in the progesterone receptor-positive (PR+) breast cancer cell line T47D.